Pharmaceutical Technology

OCTOBER 18, 2022

Gilead Sciences has entered an exclusive option and partnership agreement with MacroGenics for developing bispecific antibodies. Under the deal, the companies will leverage MacroGenics’ DART platform to develop MGD024 as well as two further bispecific research programmes.

Antibody 130

Antibody Development Sales Clinical Trials 130

Pharmaceutical Technology

JUNE 20, 2023

Developed using pharmaceutical company GSK’s pandemic adjuvant, the vaccine targets the receptor-binding domain of the SARS-CoV-2 spike protein. In a Phase III clinical trial, SKYCovione showed neutralising antibody responses against the SARS-CoV-2 parental strain.

Vaccine 363

Vaccine Vaccination Protein Clinical Trials 363

pharmaphorum

JUNE 15, 2021

Antibody flunks post-exposure prevention study. Eli Lilly meanwhile reported positive results with its bamlanivimab antibody in the BLAZE-2 study carried put in nursing homes, which found a 57% reduction in the risk of infection compared to placebo.

Antibody 119

Antibody Clinical Trials Clinical Trials Trials 119

Pharmaceutical Technology

DECEMBER 27, 2022

Along the way, mergers and acquisitions continued to happen, new drugs and devices got approved, and innovations in the clinical trial industry were introduced. Still, the country’s clinical trials sector remains insular. Tracking drug development. Tracking the news.

Clinical Trials 306

Clinical Trials Clinical Trials Trials Vaccine 306

Pharmaceutical Technology

MAY 22, 2023

SM17 is a humanised IgG4-k monoclonal antibody that targets IL-17RB to treat asthma, idiopathic pulmonary fibrosis (IPF), atopic dermatitis (AD) and other immunological disorders. SinoMab BioScience intends to commence a Phase I clinical trial in China to evaluate SM17’s safety profile.

Immune Response 273

Immune Response Clinical Trials Clinical Trials Antibody 273

World of DTC Marketing

APRIL 11, 2021

QUICK THOUGHT: People believe the COVID-19 vaccine was developed in less than a year but that’s not true. Does this explain the development of the vaccine so rapidly? If your body develops an immune response—the goal of vaccination—there is a possibility you may test positive on some antibody tests.

Vaccine 303

Vaccine Vaccination Clinical Trials Clinical Trials 303

XTalks

JANUARY 17, 2024

Estimates based on publicly available information suggest more than 40 percent of all new therapies in development are cancer treatments. Given this hotbed of activity, innovation in the space to drive faster decisions and more efficient trials is intense.

Clinical Trials 124

Clinical Trials Clinical Trials Trials Gene Therapy 124

Pharmaceutical Technology

AUGUST 24, 2022

The global immunotherapy market, which includes CAR T-cell therapy, adoptive cell therapies, checkpoint inhibitors, monoclonal antibodies, and other immunotherapies, is expected to grow by 10.1% Patients provide blood samples for clinical trial sponsors to develop and deliver these emerging immunotherapies.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

Pharmaceutical Technology

JULY 7, 2022

Brii Biosciences and TSB Therapeutics have commercially launched a long-acting neutralising antibody therapy combination, amubarvimab/romlusevimab, for Covid-19 in China. The two non-competing SARS-CoV-2 monoclonal neutralising antibodies, amubarvimab and romlusevimab are obtained from convalesced Covid-19 patients. 2 subvariants.

Antibody 264

Antibody Clinical Trials Clinical Trials Production 264

Pharmaceutical Technology

FEBRUARY 6, 2023

It explores the monoclonal antibody detection that may work against procathepsin-L (pCTS-L), a pro-inflammatory protein mediator, as the potential remedy. These anti-pCTS-L monoclonal antibodies may help in providing effective treatments for human sepsis as well as other infectious diseases, such as Covid-19.

Protein 263

Protein Research Antibody Immune Response 263

Pharmaceutical Technology

NOVEMBER 14, 2022

The antibody-drug conjugate (ADC) treatment is indicated for such patients who have previously received one to three systemic therapy regimens, irrespective of the usage of Avastin priorly. Elahere obtained the approval based on the findings on objective response rate (ORR) and duration of response (DOR) reported in the SORAYA clinical trial.

Antibody 246

Antibody FDA Approval Clinical Trials Clinical Trials 246

Pharmaceutical Technology

APRIL 26, 2023

Biotechnology company Adcentrx Therapeutics has raised $38m in Series A+ financing to advance its pipeline of new antibody-drug conjugate (ADC) therapeutics into clinical development. Adcentrx Therapeutics is focused on developing protein conjugate therapeutics to treat cancer and other life-threatening diseases.

Clinical Development 147

Clinical Development Development Clinical Trials Clinical Trials 147

Camargo

MAY 10, 2021

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. The members of the ODAC voted to continue the use of four of the six drugs it discussed during the meeting, despite failed clinical trials.

Development 185

Development Clinical Trials Clinical Trials Trials 185

Pharmaceutical Technology

SEPTEMBER 16, 2022

The US Food and Drug Administration (FDA) has granted fast track designation to Jasper Therapeutics’ antibody, JSP191, for the treatment of severe combined immunodeficiency (SCID) patients who undergo allogeneic hematopoietic stem cell transplant. . The antibody was also analysed in a total of more than 110 healthy subjects and patients. .

Antibody 130

Antibody Clinical Trials Clinical Trials Licensing 130

Bio Pharma Dive

MAY 9, 2022

Ameet Mallik takes over for founder Chris Martin at helm of the antibody drug developer after a seven-month run leading Rafael Holdings, which reported a clinical trial setback last October.

Clinical Trials 162

Clinical Trials Clinical Trials Antibody Trials 162

Pharmaceutical Technology

DECEMBER 19, 2022

With the latest development, Sanofi will licence a NK cell engager programme that acts on B7H3 from the antibody-based NK cell engager therapeutics (ANKET) platform of Innate. On choosing the candidate, the company will oversee the complete development, production and marketing.

Development 264

Development Engineer Clinical Trials Clinical Trials 264

Pharmaceutical Technology

APRIL 20, 2023

The funds will support Maxion’s KnotBody platform to develop antibodies to treat autoimmune diseases. Antibody-based therapies provide enhanced efficacy and safety whilst reducing the need for frequent administration for autoimmune disease treatment.

Development 130

Development Antibody Engineer Clinical Trials 130

Pharmaceutical Technology

APRIL 28, 2023

Biotechnology company Therini Bio has raised $36m in a Series A financing round to develop fibrin-targeted therapies to treat neurodegenerative and retinal diseases. Therini Bio will use part of the funds to advance its potential first-in-class investigational antibody, THN391, into clinical trials.

Development 130

Development Immune Response Clinical Trials Clinical Trials 130

Pharmaceutical Technology

AUGUST 12, 2022

The latest approval was based on the findings from the Phase II DESTINY-Lung02 clinical trial, which assessed the safety and efficacy of two doses of Enhertu in HER2 mutant metastatic NSCLC patients. . In the trial, 1.9% According to the interim efficacy data from a pre-specified patient cohort, a 5.4

FDA Approval 264

FDA Approval Clinical Trials Clinical Trials Engineer 264

Pharmaceutical Technology

APRIL 14, 2023

Long Covid is a health condition characterised by the continuation or development of new symptoms three months after an initial SARS-CoV-2 infection. Foralumab is a fully human anti-CD3 monoclonal antibody, which works by binding to the T-cell receptor and regulating T-cell function to reduce pulmonary inflammation.

Life Science 246

Life Science Clinical Trials Clinical Trials Trials 246

Pharmaceutical Technology

NOVEMBER 14, 2022

In a field dominated by antibodies and small molecules, two cell-therapy based approaches have come under the spotlight for showing early signs of efficacy in treating lupus. Gary Gilkeson, the trial’s principal investigator, says the study is two-thirds of the way to finishing enrollment and should complete within the next 12 months.

Antibody 362

Antibody Gene Therapy Manufacturing Trials 362

Pharmaceutical Technology

JANUARY 13, 2023

Being co-developed and co-marketed by Daiichi Sankyo along with AstraZeneca , Enhertu is a specifically engineered HER2-directed antibody-drug conjugate (ADC). Enhertu’s safety profile was consistent with the previous clinical trials.

HR 321

HR Trials Engineer Clinical Trials 321

Pharmaceutical Technology

AUGUST 8, 2022

The approval was based on findings from the international, randomised, open-label Phase III DESTINY-Breast04 clinical trial. Furthermore, Enhertu’s safety profile was in line with prior clinical trials without any new safety concerns detected. Enhertu-treated subjects had a median overall survival (OS) of 23.4

FDA Approval 264

FDA Approval HR Clinical Trials Clinical Trials 264

Pharmaceutical Technology

AUGUST 16, 2022

Q32 Bio has signed a partnership and option agreement with Horizon Therapeutics for developing ADX-914 to treat autoimmune ailments. According to the deal, Horizon will provide the funding to develop the therapy until the conclusion of its two Phase II clinical trials. A fully human anti-IL-7R?

Development 130

Development Clinical Trials Clinical Trials Regulation 130

Pharmaceutical Technology

NOVEMBER 29, 2022

Researchers at City of Hope in the US have developed a new potential therapy to treat glioblastoma multiforme (GBM), a kind of brain cancer. This chemokine is connected to the epidermal growth factor receptor (EGFR) antibody causing attachment to tumour cells. These viruses are engineered genetically for killing cancer.

Development 130

Development Research Antibody Engineer 130

STAT News

DECEMBER 11, 2022

NEW ORLEANS — An antibody treatment developed by the Belgian drugmaker Argenx raised platelet counts and stopped bleeding episodes in patients with a rare autoimmune disorder that causes the body to attack and destroy its own blood-clotting platelets.

Antibody 105

Antibody Clinical Trials Clinical Trials Drugs 105

XTalks

APRIL 22, 2022

Flow cytometric receptor occupancy assays are being increasingly used in preclinical and clinical studies. Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. What is Flow Cytometry?

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

STAT News

NOVEMBER 13, 2022

Roche reported negative results Monday from a pair of clinical trials investigating an antibody treatment for people with early-stage Alzheimer’s disease — another setback for the Swiss pharma giant’s decades-long effort to develop medicines against the memory-destroying disease.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

Camargo

NOVEMBER 29, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. Monoclonal antibodies (mAbs). Somatic cells. Gene and cellular therapies. Recombinant therapeutic proteins. Interferons.

Development 180

Development Protein Production Hormones 180

Pharmaceutical Technology

JUNE 9, 2023

Upstream Bio will use the funds to advance its UPB-101 into Phase II trials to treat asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). It is also preparing for a swift transition to Phase III development. It targets the human thymic stromal lymphopoietin receptor to inhibit signalling.

Clinical Development 147

Clinical Development Development Life Science Clinical Trials 147

XTalks

MAY 4, 2023

A blood test can detect antibodies to gluten, but a definitive diagnosis requires a biopsy of the small intestine. However, there are ongoing clinical trials for celiac disease to investigate potential new treatments. How does Beyond Celiac spread awareness about research and clinical trials for celiac disease?

Clinical Trials 98

Clinical Trials Clinical Trials Trials Immune Response 98

Pharmaceutical Technology

JANUARY 8, 2023

In 2023, the pharmaceutical industry will mark 20 years since Xolair, an anti-IgE antibody, became the first biologic approved to treat asthma. Since then, the US FDA, EMA, and other agencies have approved several biologic antibodies targeting the inflammatory cytokines IL-4, IL-13, IL-5, and others for asthma. Ongoing efforts.

Antibody 298

Antibody Trials Clinical Trials Clinical Trials 298

Camargo

DECEMBER 13, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. One common characteristic for most if not all biologics is the triggering of an immune response or anti-drug antibodies.

Development 161

Development Production Immune Response Licensing 161

Pharmaceutical Technology

MARCH 31, 2023

A study involving 765 adults indicate that Bimervax, in addition to reducing antibodies against original SARS-CoV-2 strain, led to higher levels of antibodies against Beta and Omicron variants. As new candidates emerge from development to market, a lot of doses seem to be sitting in storage boxes.

Vaccine 277

Vaccine Vaccination Immune Response Antibody 277

Pharmaceutical Technology

DECEMBER 18, 2022

Moderna’s paediatric application is based on clinical trial booster findings for Spikevax, the company’s original vaccine. Additionally, the application included findings from a Phase II/III clinical trial of mRNA-1273.214. 5), mRNA-1273.

Gene Therapy 304

Gene Therapy Vaccine Vaccination Clinical Trials 304

pharmaphorum

JANUARY 21, 2022

Research led by UCLH, UCL and the Francis Crick Institute found that the booster dose successfully stimulates antibody levels that neutralise Omicron. Overall, antibody levels were nearly 2.5 The post Covid vaccine booster raises antibody levels in fight against Omicron appeared first on.

Antibody 115

Antibody Vaccination Vaccine Genotype 115

Worldwide Clinical Trials

JUNE 21, 2024

The 2024 ASCO Annual Meeting from the American Society of Clinical Oncology is a fantastic platform for clinical researchers to discuss the latest advancements and challenges in oncology research. Currently, there are 12 approved ADC drugs, and several hundred more are in the development pipeline.

Antibody 162

Antibody Clinical Trials Clinical Trials In-Vitro 162